JAK2 Mutation Marker

Overview

JAK2 mutation marker refers to a somatic mutation in the JAK2 gene, most commonly the JAK2 V617F variant, that abnormally activates the JAK‑STAT signaling pathway and drives uncontrolled myeloid proliferation. This mutation is found in the majority of polycythemia vera and in a substantial proportion of essential thrombocythemia and primary myelofibrosis. Detection of a JAK2 mutation (in blood or bone marrow) strongly supports clonal myeloproliferative neoplasm rather than a reactive cause of elevated blood counts. As such, JAK2 testing is clinically useful for diagnosing and classifying myeloproliferative disorders and guiding prognostic and therapeutic decisions.

Clinical Use Cases

  • Diagnosing suspected polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
  • Differentiating clonal hematologic neoplasm from reactive erythrocytosis or thrombocytosis.
  • Supporting risk stratification and decision‑making about targeted JAK inhibitors (e.g., ruxolitinib).
  • Monitoring disease evolution or minimal residual disease in some settings (more in research and specialized centers).

Specimen Types

  • Peripheral blood (genomic DNA from leukocytes is standard for routine testing).
  • Bone marrow aspirate or biopsy (for confirmation in selected cases).

Measurement Methods

  • Polymerase chain reaction (PCR)‑based assays, including allele‑specific PCR or quantitative real‑time PCR for JAK2 V617F.
  • Next‑generation sequencing (NGS) panels detecting JAK2 V617F and other exon 12 or rarer JAK2 mutations.
  • Sanger sequencing (used less commonly as a first‑line test).

Test Preparation and Influencing Factors

  • No fasting or special preparation required; whole‑blood collection in EDTA or ACD is standard.
  • Prior blood transfusion or bone marrow transplantation can dilute or suppress the mutant clone, leading to false‑negative or low‑level detection.
  • Assay sensitivity and quality control (e.g., detection limit) affect the ability to detect low‑variant‑allele‑frequency clones.
  • False positives are rare; interpretation should always be done in the context of blood counts and other clinical findings.

Synonyms

  • JAK2 V617F mutation.
  • Janus kinase 2 mutation.
  • JAK2 activation mutation (general term).

Further Reading